tbuckley/cabot-search huggingface dataset:
TCT-663 Impact of Successful Percutaneous Coronary Intervention on Chronic Total Occlusion Outcomes in Elderly Patients
Authors: Se Yeon Choi, Seung-Woon Rha, Byoung Geol Choi, Jae Kyeong Byun, Ahmed Mashaly, Won Young Jang, Woo Hyeun Kim, Eun Jin Park, Ja Yeon Choi, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing
Authors: Jason P. Lott, Denise M. Boudreau, Ray L. Barnhill, Martin A. Weinstock, Eleanor Knopp, Michael W. Piepkorn, David E. Elder, Steven R. Knezevich, Andrew Baer, Anna N. A. Tosteson, Joann G. Elmore
Journal: JAMA Dermatology (2017)

Population-based information on the distribution of histologic diagnoses associated with skin biopsies is unknown. Electronic medical records (EMRs) enable automated extraction of pathology report data to improve our epidemiologic understanding of skin biopsy outcomes, specifically those of melanocytic origin. To determine population-based frequencies and distribution of histologically confirmed melanocytic lesions. A natural language processing (NLP)-based analysis of EMR pathology reports of adult patients who underwent skin biopsies at a large integrated health care delivery system in the US Pacific Northwest from January 1, 2007, through December 31, 2012. Skin biopsy procedure. The primary outcome was histopathologic diagnosis, obtained using an NLP-based system to process EMR pathology reports. We determined the percentage of diagnoses classified as melanocytic vs nonmelanocytic lesions. Diagnoses classified as melanocytic were further subclassified using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) reporting schema into the following categories: class I (nevi and other benign proliferations such as mildly dysplastic lesions typically requiring no further treatment), class II (moderately dysplastic and other low-risk lesions that may merit narrow reexcision with <5-mm margins), class III (eg, melanoma in situ and other higher-risk lesions warranting reexcision with 5-mm to 1-cm margins), and class IV/V (invasive melanoma requiring wide reexcision with ≥1-cm margins and potential adjunctive therapy). Health system cancer registry data were used to define the percentage of invasive melanoma cases within MPATH-Dx class IV (stage T1a) vs V (≥stage T1b). A total of 80 368 skin biopsies, performed on 47 529 patients, were examined. Nearly 1 in 4 skin biopsies were of melanocytic lesions (23%; n = 18 715), which were distributed according to MPATH-Dx categories as follows: class I, 83.1% (n = 15 558); class II, 8.3% (n = 1548); class III, 4.5% (n = 842); class IV, 2.2% (n = 405); and class V, 1.9% (n = 362). Approximately one-quarter of skin biopsies resulted in diagnoses of melanocytic proliferations. These data provide the first population-based estimates across the spectrum of melanocytic lesions ranging from benign through dysplastic to malignant. These results may serve as a foundation for future research seeking to understand the epidemiology of melanocytic proliferations and optimization of skin biopsy utilization.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
Authors: Catherine Van Poznak, Mark R. Somerfield, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Mark J. Clemons, Sukhbinder K. Dhesy-Thind, Melissa S. Dillmon, Andrea Eisen, Elizabeth S. Frank, Reshma Jagsi, Rachel Jimenez, Richard L. Theriault, Theodore A. Vandenberg, Gary C. Yee, Beverly Moy
Journal: Journal of Clinical Oncology (2017)

Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases. Recommendations Patients with breast cancer who have evidence of bone metastases should be treated with BMAs. Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. The Update Committee recommends that the current standard of care for supportive care and pain management-analgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and referral to supportive care and pain management-be applied. Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .
The Digital Slide Archive: A Software Platform for Management, Integration, and Analysis of Histology for Cancer Research
Authors: David A. Gutman, Mohammed Khalilia, Sanghoon Lee, Michael Nalisnik, Zach Mullen, Jonathan Beezley, Deepak R. Chittajallu, David Manthey, Lee A.D. Cooper
Journal: Cancer Research (2017)

Tissue-based cancer studies can generate large amounts of histology data in the form of glass slides. These slides contain important diagnostic, prognostic, and biological information and can be digitized into expansive and high-resolution whole-slide images using slide-scanning devices. Effectively utilizing digital pathology data in cancer research requires the ability to manage, visualize, share, and perform quantitative analysis on these large amounts of image data, tasks that are often complex and difficult for investigators with the current state of commercial digital pathology software. In this article, we describe the Digital Slide Archive (DSA), an open-source web-based platform for digital pathology. DSA allows investigators to manage large collections of histologic images and integrate them with clinical and genomic metadata. The open-source model enables DSA to be extended to provide additional capabilities. Cancer Res; 77(21); e75-78. ©2017 AACR.
Association between lung cancer somatic mutations and occupational exposure in never-smokers
Authors: Christophe Paris, Pascal Do, Bénédicte Mastroianni, Adrien Dixmier, Patrick Dumont, Eric Pichon, Christos Chouaid, Bruno Coudert, Pascal Foucher, Séverine Fraboulet, Myriam Locatelli-Sanchez, Nathalie Baize, Eric Dansin, Lionel Moreau, Michel Vincent, Pascale Missy, Franck Morin, Denis Moro-Sibilot, Sébastien Couraud
Journal: European Respiratory Journal (2017)

Occupational exposure constitutes a common risk factor for lung cancer. We observed molecular alterations in 73% of never-smokers, 35% of men and 8% of women were exposed to at least one occupational carcinogen. We report herein associations between molecular patterns and occupational exposure. BioCAST was a cohort study of lung cancer in never-smokers that reported risk factor exposure and molecular patterns. Occupational exposure was assessed via a validated 71-item questionnaire. Patients were categorised into groups that were unexposed and exposed to polycyclic aromatic hydrocarbons (PAH), asbestos, silica, diesel exhaust fumes (DEF), chrome and paints. Test results were recorded for EGFR, KRAS, HER2, BRAF and PIK3 mutations, and ALK alterations. Overall, 313 out of 384 patients included in BioCAST were analysed. Asbestos-exposed patients displayed a significantly lower rate of EGFR mutations (20% versus 44%, p=0.033), and a higher rate of HER2 mutations (18% versus 4%, p=0.084). ALK alterations were not associated with any occupational carcinogens. The DEF-exposed patients were diagnosed with a BRAF mutation in 25% of all cases. Chrome-exposed patients exhibited enhanced HER2 and PIK3 mutation frequency. Given its minimal effects in the subgroups, we conclude that occupational exposure slightly affects the molecular pattern of lung cancers in never-smokers. In particular, asbestos-exposed patients have a lower chance of EGFR mutations.
Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy
Authors: Morgane Solis, Aurélie Velay, Raphaël Porcher, Pilar Domingo-Calap, Eric Soulier, Mélanie Joly, Mariam Meddeb, Wallys Kack-Kack, Bruno Moulin, Siamak Bahram, Françoise Stoll-Keller, Heidi Barth, Sophie Caillard, Samira Fafi-Kremer
Journal: Journal of the American Society of Nephrology (2017)

BK virus–associated nephropathy (BKVAN) causes renal allograft dysfunction. The current management of BKVAN relies on pre-emptive adaptation of immunosuppression according to viral load monitoring. However, this empiric strategy is not always successful. Therefore, pretransplant predictive markers are needed. In a prospective longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors. To assess the value of BKV genotype–specific neutralizing antibody (NAb) titers as a predictive marker for BKV replication, we measured BKV DNA load and NAb titers at transplant and followed patients for 24 months. After transplant, 52 (31%) patients displayed BKV replication: 24 (46%) patients were viruric and 28 (54%) patients were viremic, including 13 with biopsy-confirmed BKVAN. At any time, patients with high NAb titers against the replicating strain had a lower risk of developing BKV viremia (hazard ratio [HR], 0.44; 95% confidence interval [95% CI], 0.26 to 0.73; P =0.002). Each log 10 increase in NAb titer decreased the risk of developing viremia by 56%. Replicating strains were consistent with donor transmission in 95% of cases of early BKV replication. Genotype mismatch between recipients’ neutralization profiles before transplant and their subsequently replicating strain significantly increased the risk of developing viremia (HR, 2.27; 95% CI, 1.06 to 4.88; P =0.04). A NAb titer against the donor’s strain &lt;4 log 10 before transplant significantly associated with BKV replication after transplant (HR, 1.88; 95% CI, 1.06 to 3.45; P =0.03). BKV genotype–specific NAb titers may be a meaningful predictive marker that allows patient stratification by BKV disease risk before and after transplant.
Retracted: Transplantation of brown adipose tissue inhibits atherosclerosis in apoE−/− mice: contribution of the activated FGF-21-adiponectin axis
Authors: Masakazu Kikai, Hiroyuki Yamada, Noriyuki Wakana, Kensuke Terada, Keita Yamamoto, Naotoshi Wada, Shinichiro Motoyama, Makoto Saburi, Takeshi Sugimoto, Daisuke Irie, Taku Kato, Hiroyuki Kawahito, Takehiro Ogata, Satoaki Matoba
Journal: Cardiovascular Research (2017)
Response to Comment on Craig et al. Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. Diabetes Care 2017;40:1034–1040
Authors: Maria E. Craig, Nicole Prinz, Claire T. Boyle, Fiona M. Campbell, Timothy W. Jones, Sabine E. Hofer, Jill H. Simmons, Naomi Holman, Elaine Tham, Elke Fröhlich-Reiterer, Stephanie DuBose, Helen Thornton, Bruce King, David M. Maahs, Reinhard W. Holl, Justin T. Warner
Journal: Diabetes Care (2017)

Maltoni et al. (1) report a high prevalence (9.8%) of celiac disease (CD) in 2,164 youth with type 1 diabetes from five pediatric diabetes centers in northern Italy. This is considerably higher than in our recent report (3.5%) from three continents (U.K./Austria/Germany, U.S., and Australia) (2) and the pooled prevalence of 5.1% in a systematic review of CD in type 1 diabetes (3). Maltoni et al. propose that their higher rate of CD may be explained by more active screening programs in Italy. We agree that this is likely to be a contributing factor, as previous reports of high rates of coexisting CD and type 1 diabetes in Italy (4) and of CD in the general population may have heightened awareness of CD risk. It is of note, however, that we used a stringent definition of biopsy-proven CD and that a further …
Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer
Authors: Xiaoli Chen, Meiyu Dai, Hongzhen Zhu, Jinwan Li, Zhizhuo Huang, Xuexiang Liu, Yujie Huang, Jingfan Chen, Shengming Dai
Journal: Molecular Cancer (2017)

A growing number of evidence has indicated that long non-coding RNAs (lncRNA) may have many functions in the development and progression of cancer, and cloud serve as good diagnostic and prognostic biomarkers in cancers. However, these studies often revealed the changes of lncRNAs within a specific cancer type. Here, we focused on BLACAT1 and provided a comprehensive pan-cancer analysis to evaluate the diagnostic and prognostic values of BLACAT1. The expression data of BLACAT1 were came from the quantitative real-time polymerase chain reaction (qRT-PCR) and The Cancer Genome Atlas (TCGA) database, respectively. Our results showed that the change of serum BLACAT1 expression was similar to those in matched tissues. The expression level of BLACAT1 both in serum and tissues in multiple cancer types were significantly upregulated compared to those of matched non-cancer participants. The serum BLACAT1 had a high diagnostic performance among these 12 types of cancer. The relative AUC of serum BLACAT1 in cancer patients ranged from 0.833 to 0.967 compared to that in healthy subjects. Surprisingly, Kaplan-Meier survival analysis revealed that the high expression level of BLACAT1 was significantly associated with poor overall survival only in uterine corpus endometrial carcinoma (p = 0.002, log-rank test). These findings demonstrated that BLACAT1 could act as a non-specific diagnostic biomarker for cancers and a potential biomarker for prognosis prediction of endometrial cancer.
Confirmación de la Interrupción de la transmisión del sarampión autóctono en Cataluña, España
Authors: L Salleras, A Domínguez, N Torner
Journal: Eurosurveillance (2001)

Entre noviembre de 1998 y diciembre de 2000, un total de 84 casos sospechosos de sarampion fue notificado en Cataluna (6.090.040 habitantes). De los 73 casos analizados en laboratorio (87%), 20 presentaban anticuerpos IgM especificos del sarampion y 3 estaban relacionados epidemiologicamente con un caso confirmado. De estos 23 casos confirmados, 13 eran autoctonos, con los ultimos dos casos declarados en junio de 1999 y julio de 2000. Estos resultados confirman el exito del programa de eliminacion del sarampion implantado en 1998 en Cataluna.
“Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
Authors: Katherine C. Kurnit, Ann M. Bailey, Jia Zeng, Amber M. Johnson, Md. Abu Shufean, Lauren Brusco, Beate C. Litzenburger, Nora S. Sánchez, Yekaterina B. Khotskaya, Vijaykumar Holla, Amy Simpson, Gordon B. Mills, John Mendelsohn, Elmer Bernstam, Kenna Shaw, Funda Meric-Bernstam
Journal: Cancer Research (2017)

High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable cancers. However, navigating the scientific literature to make evidence-based clinical decisions based on molecular profiling results is overwhelming for many oncology clinicians and researchers. The Personalized Cancer Therapy website (www.personalizedcancertherapy.org) was created to provide an online resource for clinicians and researchers to facilitate navigation of available data. Specifically, this resource can be used to help identify potential therapy options for patients harboring oncogenic genomic alterations. Herein, we describe how content on www.personalizedcancertherapy.org is generated and maintained. We end with case scenarios to illustrate the clinical utility of the website. The goal of this publicly available resource is to provide easily accessible information to a broad oncology audience, as this may help ease the information retrieval burden facing participants in the precision oncology field. Cancer Res; 77(21); e123-6. ©2017 AACR.
Synergistic interactions between the synthetic retinoid Tamibarotene (TM411) and Corticosteroids in human myeloma cells
Authors: Tomoya Fukui, Yasuo Kodera, Fumiko Taguchi, Terufumi Kato, Takashi Watanabe, Noriyuki Masuda, Kazuto Nishio, Fumiaki Koizumi
Journal: Cancer Research (2008)

2770   Multiple myeloma (MM) remains an incurable B-cell malignancy despite aggressive combination chemotherapy. Tamibarotene (TM411) is a synthetic retinoic acid receptor (RAR)-alpha/ -beta selective retinoid that is chemically more stable to light, heat and oxidation than All-trans retinoic acid (ATRA). It does not bind to RAR-gamma; therefore, TM411 would be expected to have fewer adverse events related to RAR-gamma. In the present study, we evaluated the anti-tumor effect of TM411 and the combination effects of TM411 and corticosteroids, one of the most effective agents against MM, using RPMI8226, MM.1S and U266 cell lines. The growth-inhibitory effects of TM411 were 2-10 fold more potent than those of ATRA with an inhibitory concentration 50% (IC50) value of about 3 nM in RPMI8226 and 10 nM in MM.1S cells. TM411 did not inhibit the cell growth of U266 cells. The expression of RAR -alpha and -beta was detected only in sensitive RPMI8226 and MM.1S cells. The combination of TM411 and corticosteroid induced remarkable synergistic effect in both RPMI8226 and MM.1S cells assessed by the in vitro isoborogram method. To elucidate the mechanism of the synergistic effect, the effect of TM411-exposure on IL-6 related molecules, which induces growth, survival and drug resistance in MM, was examined by reverse transcription polymerase chain reaction and immunoblotting. Increased expression of the IL-6 receptor, phosphorylated MAPK and Akt was observed after exposure to corticosteroid. On the other hand, TM411 inhibited the increased expression of IL-6 receptor, phosphorylated MAPK and Akt induced by corticosteroid. These findings suggested that this modification by TM411 was the possible mechanism for the synergistic effect. To further elucidate the synergistic effects, we plan to evaluate the combined therapeutic effect of drug administration on pre-existing tumors.
RE: Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males
Authors: WeiLin Mao
Journal: Hepatology (2012)

The recent publication in Volume 55 of HEPATOLOGY Higher Serum Testosterone Is Associated with Increased Risk of Advanced Hepatitis C-Related Liver Disease in Males1 concluded that serum total testosterone levels are associated with higher rates of fibrosis and inflammation in hepatitis C virus (HCV)-infected men. The hypothesis was raised that serum testosterone may be implicated in the pathogenesis of HCV-related advanced liver disease in males. While this publication investigated the association of total serum testosterone with fibrosis scores and inflammatory activity, sex estradiol levels were not determined. The liver is a hormone-sensitive organ, and in fact both normal liver and hepatocellular carcinoma tissues from male and female mammals have been shown to express specific estrogen receptors (ERs). Experimentally, estrogens may act as liver tumor inducers or promoters in vivo.2, 3 In fact, estrogens are involved in the regulation of hepatocyte proliferation: a "feminization" of the hepatic microenvironment occurs after partial hepatectomy in rats and humans with an increase in estrogen levels and a concomitant reduction of testosterone levels.4, 5 The source of estrogens in men is from the aromatization of androgens and, broken down in the liver, the relationship may relate to the severity of liver disease. Therefore, serum total testosterone is not an accurate reflection of sex hormone status in cirrhosis and estradiol levels should also be determined in this patient group. WeiLin Mao X.X.*, * Department of Clinical Laboratory, First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China.
Reply to Riché et al.: Sevoflurane in Acute Respiratory Distress Syndrome: Are Lung Protection and Anesthesia Depth Influenced by Pulmonary Morphology?
Authors: Raiko Blondonnet, Thomas Godet, Emmanuel Futier, Jean-Etienne Bazin, Jean-Michel Constantin, Matthieu Jabaudon
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
TNF-α–induced protein 3 levels in lung dendritic cells instruct T H 2 or T H 17 cell differentiation in eosinophilic or neutrophilic asthma
Authors: Heleen Vroman, Ingrid M. Bergen, Jennifer A.C. van Hulst, Menno van Nimwegen, Denise van Uden, Martijn J. Schuijs, Saravanan Y. Pillai, Geert van Loo, Hamida Hammad, Bart N. Lambrecht, Rudi W. Hendriks, Mirjam Kool
Journal: Journal of Allergy and Clinical Immunology (2017)
Abstract 18596: Low Fasting Plasma Glucose is Associated With Increased Mortality in Patients With Advanced Heart Failure: “Fasting Glucose Paradox"
Authors: Vojtech Melenovsky, Marketa Segetova, Jan Benes, Petr Stavek, Jan Kovar, Terezie Pelikanova
Journal: Circulation (2016)

Introduction: Glucose homeostasis is often abnormal in advanced heart failure (HF). Epidemiology studies suggested U-shape relation between fasting plasma glucose (FPG) and mortality in general pop...
TCT-736 Characteristics, Clinical Presentation, and Outcomes of Patients with Recurrent In-stent Restenosis of Drug-Eluting Stents Compared to Patients with Single Episode of In-stent Restenosis
Authors: Kyle Buchanan, M. Chadi Alraies, Toby Rogers, None Arie Steinvil, Edward Koifman, Linzhi Xu, Rebecca Torguson, Itsik Ben-Dor, Augusto Pichard, William Suddath, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2017)
TCT-332 FANTOM II Trial: Safety &amp; Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report on Initial 24 Month Outcomes
Authors: Alexandre Abizaid, Carrie Didier, Norbert Frey, Matthias Lutz, Joachim Weber-Albers, Darius Dudek, Bernard Chevalier, Alexandra Lansky, Jeffrey Anderson
Journal: Journal of the American College of Cardiology (2017)
Brote de gastroenteritis vírica Norwalk-like en turistas de viaje en Andorra, enero-febrero de 2002
Authors: B Pedalino, E Feely, P McKeown, B Foley, B Smyth, A Moren
Journal: Eurosurveillance (2003)

Se realizo un estudio de cohorte retrospectivo para investigar un brote de gastroenteritis virica Norwalk-like en turistas irlandeses de viaje en Andorra en enero-febrero de 2002. Los resultados preliminares mostraron una mayor exposicion al riesgo en turistas hospedados en Soldeu que consumieron cubitos de hielo en sus bebidas (OR = 2,5, IC 95% [1,3-4,6)], tras una regresion logistica y el ajuste por sexo y consumo de agua).